[
    [
        {
            "time": "2018-01-02",
            "original_text": "Roche Receives EC Approval for Label Expansion of Hemlibra",
            "features": {
                "keywords": [
                    "Roche",
                    "EC Approval",
                    "Label Expansion",
                    "Hemlibra"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Roche Receives EC Approval for Label Expansion of Hemlibra",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "3 Dividend Aristocrats to Buy and Hold Forever",
            "features": {
                "keywords": [
                    "Dividend Aristocrats",
                    "Buy",
                    "Hold",
                    "Forever"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividends",
                    "investing"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 Dividend Aristocrats to Buy and Hold Forever",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "The Timely Ten- Blue Chip Buys with Value and Yield",
            "features": {
                "keywords": [
                    "Timely Ten",
                    "Blue Chip",
                    "Value",
                    "Yield"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "blue chip",
                    "value investing"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Timely Ten- Blue Chip Buys with Value and Yield",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades",
            "features": {
                "keywords": [
                    "Blue Chip",
                    "Drug Stocks",
                    "Reckoning",
                    "Downgrades"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]